Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: Nationwide, population based case-control study

BMJ (Online)

Volumn 346, Issue 7914, 2013, Pages

  Robinson, David ^a,b   Garmo, Hans ^c,f   Bill Axelson, Anna ^d   Mucci, Lorelei ^e   Holmberg, Lars ^c,f   Stattin, Pär ^a,g  

^a UMEÅ UNIVERSITY   (Sweden)

^b RYHOV COUNTY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DRUG EXPOSURE; GLEASON SCORE; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SWEDEN; TREATMENT DURATION;

5-ALPHA REDUCTASE INHIBITORS; CASE-CONTROL STUDIES; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SWEDEN;

EID: 84879708124     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f3406     Document Type: Article

References (30)

1. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24. (Pubitemid 36859473)
2. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
3. Nacusi LP, Tindall DJ. Targeting 5alpha-reductase for prostate cancer prevention and treatment. Nat Rev Urol 2011;8:378-84.
4. US Food and Drug Administration. FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. 2011. www.fda.gov/Drugs/DrugSafety/ucm258314.htm.
5. Cohen YC, Liu KS, Heyden NL, Carides AD, Anderson KM, Daifotis AG, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1366-74. (Pubitemid 351767189)
6. Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res (Phila) 2008;1:182-6.
7. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Jr., Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) 2008;1:174-81.
8. Bostwick DG, Qian J, Civantos F, Roehrborn CG, Montironi R. Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer 2004;2:228-35. (Pubitemid 38500693)
9. Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE Study. J Urol 2011;185:126-31.
10. Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 2003;44:650-5. (Pubitemid 37542921)
11. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98:1128-33. (Pubitemid 44288787)
12. Muthusamy S, Andersson S, Kim HJ, Butler R, Waage L, Bergerheim U, et al. Estrogen receptor beta and 17beta-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer. Proc Natl Acad Sci U S A 2011;108:20090-4.
13. Van Hemelrijck M, Wigertz A, Sandin F, Garmo H, Hellstrom K, Fransson P, et al. Cohort profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol 2012, doi:10.1093/ije/ dys068.
14. National Prostate Cancer Register. Prostate cancer: national quality report for the year of diagnosis 2010 from the National Prostate Cancer Register (NPCR). 2012. www.cancercentrum.se/Global/RCCUppsalaOrebro/V%c3%a5rdprocesser/ urologi/prostatacancer/rapporter/NPCR-Repport-ENG-120523.pdf.
15. Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007;41:456-77. (Pubitemid 350207540)
16. Hagel E, Garmo H, Bill-Axelson A, Bratt O, Johansson JE, Adolfsson J, et al. PCBaSe Sweden: A register-based resource for prostate cancer research. Scand J Urol Nephrol 2009:1-8.
17. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009;24:659-67.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. (Pubitemid 17055592)
19. Socialstyrelsen. The national patient register. www.socialstyrelsen.se/ register/halsodataregister/patientregistret/inenglish.
20. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8:162-200.
21. Cox D, Oakes D. Analysis of survival data. Chapman & Hall/CRC, 1984.
22. World Health Organization. Definition and general considerations. 2009. www.whocc.no/ddd/definition-and-general-considera/.
23. Ihaka R, Gentleman R. A language for data analysis and graphics. J Comp Graph Stat 1996;5:299-314.
24. Hamilton RJ, Freedland SJ. 5-alpha reductase inhibitors and prostate cancer prevention: where do we turn now? BMC Med 2011;9:105.
25. Roehrborn CG, Andriole GL, Wilson TH, Castro R, Rittmaster RS. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Eur Urol 2011;59:244-9.
26. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet 2012;379:1103-11.
27. Murtola TJ, Tammela TL, Maattanen L, Ala-Opas M, Stenman UH, Auvinen A. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer 2009;101:843-8.
28. Orsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. Eur Urol 2011;60:691-8.
29. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338:557-63. (Pubitemid 28114643)
30. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98. (Pubitemid 37542987)